Home > Oncology > ESMO 2021 > Lung Cancer > TCR clonality predicts pembrolizumab response in NSCLC

TCR clonality predicts pembrolizumab response in NSCLC

Presented By
Dr Afef Abed, Edith Cowan University, Australia
ESMO 2021
Pre-treatment T-cell receptor (TCR) clonality and reduced diversity predicted response rate in non-small cell lung cancer (NSCLC) patients with high PD-L1 treated with pembrolizumab. Due to recombination and cellular selection, the immune system is able to produce up to 1011 different TCRs. Increased clonality, reduced diversity, and increased convergence of TCRs have been suggested to reflect clonal expansion of antigen-specific T cells in the tumour microenvironment and to correlate with improved overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Moreover, increased clonality has been linked to increased risk of developing immune related toxicity. To further explore the association between TCR repertoire and treatment outcomes, Australian investigators analysed the pre-treatment TCR repertoire in 29 patients with NSCLC (PD-L1 ≥50%) treated with single-agent pembrolizumab and follow-up for at least 1...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on